Trending News Today: Pfizer Begins Trial for Duchenne Muscular Dystrophy Gene Therapy

Pfizer has started a phase 1b trial for a Duchenne muscular dystrophy (DMD) gene therapy acquired as part of its $700 million takeover of Bamboo Therapeutics in 2016, FierceBiotech reported. The trial got underway when the first patient received a single infusion of mini-dystrophin candidate PF-06939926, according to the article. The target enrollment in the trial is 12 patients and Pfizer is hoping to have the first results available in the first half of next year, the article noted.
 
A federal judge in Ohio has scheduled a trial date for part of a massive combined lawsuit against drug manufacturers and distributors over the opioid epidemic, according to The Hill. According to the article, Judge Dan Polster set a March 2019 trial date for cases from 3 of the cities and counties that are suing drug companies. The cases are being closely watched to see if they produce a settlement that forces changes meant to fight the opioid epidemic, The Hill reported. 
 
Bipartisan senators are calling for Attorney General Jeff Sessions to stop efforts by the Drug Enforcement Agency (DEA) to slow medical marijuana research, The Hill reported. According to the article, at least 25 manufacturers have formally applied to produce federally-approved research-grade marijuana, but the DEA has not approved those requests. The senators asked Sessions for a commitment that the DEA would resolve all outstanding applications by August 11, according to The Hill.


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Top news of the day from across the health care landscape.
Treatment with tezepelumab reduced annual asthma exacerbation rates in patients with severe asthma without an eosinophilic phenotype.
Officials with the FDA have approved a new dosage strength (16 milligrams/4 milligrams) of buprenorphine and naloxone sublingual film for the maintenance treatment of opioid dependence.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$